Written By: Kalyani Boharapi,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) to children and adolescents aged 2–17 years with chronic medical conditions who have completed a primary pneumococcal vaccination series.
CAPVAXIVE is now the first pneumococcal conjugate vaccine in the United States specifically studied and indicated for this high-risk pediatric population.
Broader Serotype Coverage
CAPVAXIVE targets 21 Streptococcus pneumoniae serotypes, including 11 not contained in current pediatric conjugate vaccine series. CDC surveillance analyses cited by Merck suggest CAPVAXIVE covers serotypes responsible for approximately 79% of invasive pneumococcal disease (IPD) cases in children with chronic conditions, including about 40% attributable to serotypes unique to the vaccine. These figures reflect epidemiological burden rather than vaccine efficacy.
Phase 3 STRIDE-13 Trial
Approval was supported by STRIDE-13 (NCT06177912), a randomized, double-blind, active comparator-controlled Phase 3 study enrolling 874 children and adolescents aged 2–17 years with chronic medical conditions associated with increased pneumococcal disease risk. Participants received either CAPVAXIVE (n=527) or PPSV23 (n=347).
CAPVAXIVE met noninferiority criteria for all 12 serotypes shared with PPSV23 and generated significantly higher opsonophagocytic activity against its nine unique serotypes. The vaccine also produced robust immune responses against serotype 15B, which is cross-reactive with serotype 15C.
Safety Profile
CAPVAXIVE showed a safety profile comparable to PPSV23, with most solicited adverse reactions resolving within three days. The most common adverse events included injection-site pain, erythema, swelling, fatigue, headache, malaise, and irritability.
Serious adverse events occurred in 5.5% of CAPVAXIVE recipients and 7.2% of PPSV23 recipients, with no clinically meaningful imbalance between treatment groups. One vaccine-related serious adverse event, syncope requiring hospitalization, was reported following CAPVAXIVE administration.
Clinical Significance
Investigators highlighted CAPVAXIVE’s ability to extend protection against pneumococcal serotypes not included in existing pediatric conjugate vaccine series. The expanded indication addresses a persistent disease burden among children and adolescents with chronic medical conditions who remain vulnerable to invasive pneumococcal infections despite routine immunization.
Merck stated that the approval broadens protection options for a population with ongoing unmet medical needs and reinforces efforts to reduce the impact of pneumococcal disease across age groups.
Clinical and Public Health Impact
The pediatric expansion broadens CAPVAXIVE’s role beyond adult vaccination and strengthens its position across age groups. CAPVAXIVE is already approved for the prevention of invasive pneumococcal disease in adults and for pneumococcal pneumonia under the FDA’s accelerated approval pathway.
The new indication may influence future vaccination recommendations for children and adolescents with chronic medical conditions who remain at elevated risk for invasive pneumococcal disease despite completing routine vaccination schedules.
What This Means for Patients
Children and adolescents with chronic medical conditions such as diabetes, heart disease, lung disease, kidney disease, or liver disease remain at elevated risk for serious pneumococcal infections even after completing routine childhood vaccination schedules. The FDA’s expanded approval of CAPVAXIVE provides an additional option that extends protection to serotypes not included in current pediatric conjugate vaccines. By broadening coverage to 21 serotypes including 11 unique to CAPVAXIVE the vaccine may help reduce the risk of invasive infections such as meningitis, bloodstream infections, and severe pneumonia in vulnerable patients. For families and clinicians, this approval represents a meaningful advance in safeguarding high-risk children against persistent pneumococcal disease burden.
Reference
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.